U.S. Trade Policies Cast Uncertainty Over Ireland’s Corporate Tax Windfall

Ireland’s booming corporate tax revenue, heavily reliant on U.S. multinational companies, faces growing uncertainty as American trade policies evolve, the Irish Fiscal Advisory Council (IFAC) has warned.

Corporate tax receipts in Ireland have surged sevenfold since 2014, now making up nearly one-third of total government revenues. This sharp rise has largely been fueled by a small cluster of U.S. tech and pharmaceutical giants that dominate Ireland’s export economy. According to IFAC, about 87% of all corporate taxes paid by U.S.-owned firms come from these two industries.

So far, Ireland’s major pharmaceutical and technology exporters have avoided direct U.S. tariffs. In fact, pharmaceutical exports have surged as companies accelerated shipments to the U.S. ahead of potential trade barriers. By April 2025, Ireland’s pharma exports had already exceeded the record total for all of 2024. Much of this growth came from exports of active ingredients used in popular weight-loss drugs, providing a short-term boost to corporate tax receipts.

However, the watchdog cautioned that this windfall might not last. While recent gains have strengthened public finances, the long-term outlook remains uncertain. The United States aims to expand domestic manufacturing capacity, a move that could shift pharmaceutical production away from Ireland over time.

IFAC noted that multiple forces are shaping the sector’s future — from possible tariffs and drug price reforms to booming global demand and the launch of new blockbuster medicines. “Corporation tax revenues from pharma could go up by a lot or down by a lot,” it warned.

Although other manufacturing sectors like beverages and medical devices may feel the sting of tariffs, they represent only 4% of Ireland’s total corporate tax take, leaving the U.S.-linked pharma and tech giants as the country’s most critical — and most vulnerable — taxpayers.